Immunology of human schistosomiasis: Off the beaten path

Parasite Immunology

Volumn 27, Issue 7-8, 2005, Pages 309-316

  Secor, W Evan ^a,b  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b MS F13 ^*  (United States)

Author keywords

Anaemia; Co infection; HIV; Immune response; Mass treatment; Schistosomiasis

Indexed keywords

ANEMIA; DISEASE COURSE; DISEASE PREDISPOSITION; GENETIC SUSCEPTIBILITY; HEALTH PROGRAM; HOST PARASITE INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGY; MORBIDITY; PRIORITY JOURNAL; REINFECTION; REVIEW; SCHISTOSOMIASIS;

ANEMIA; ANIMALS; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HUMANS; MALE; PUBLIC HEALTH; SCHISTOSOMIASIS;

EID: 25144487619     PISSN: 01419838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-3024.2005.00778.x     Document Type: Review

References (93)

1. Dessein A, Kouriba B, Eboumbou C, et al. Interleukin-13 in the skin and interferon-γ in the liver are key players in immune protection in human schistosomiasis. Immunol Rev 2004; 201: 180-190.
2. Vennervald BJ & Dunne DW. Morbidity in schistosomiasis: an update. Curr Opin Infect Dis 2004; 17: 439-447.
3. Todd CW & Colley DG. Practical and ethical issues in the development of a vaccine against schistosomiasis mansoni. Am J Trop Med Hyg 2002; 66: 348-358.
4. James SL & Colley DG. Progress in vaccine development. In Schistosomiasis, ed. Mahmoud AAF. London: Imperial College Press; 2001: 469-495.
5. King CH, Dickman K & Tisch DJ. Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet 2005; 365: 1561-1569.
6. McGarvey ST. Schistosomiasis: Impact on childhood and adolescent growth, malnutrition, and morbidity. Sem Ped Infect Dis 2000; 11: 269-274.
7. WHA. Fifty-fourth World Health Assembly, resolution WHA54·19. 2001
8. Tanabe M. Haemostatic abnormalities in hepatosplenic schistosomiasis mansoni. Parasitol Int 2003; 52: 351-359.
9. Stephenson LS, Latham MC, Kurz KM, Miller D, Kinoti SN & Oduori ML. Urinary iron loss and physical fitness of Kenyan children with urinary schistosomiasis. Am J Trop Med Hyg 1985; 34: 322-330.
10. Friedman JF, Kanzaria HK, Acosta LP, et al. Relationship between Schistosoma japonicum and nutritional status among children and young adults in Leyte, the Philippines. Am J Trop Med Hyg 2005; 72: 527-533.
11. Weiss G & Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011-1023.
12. Means RT. Advances in the anemia of chronic disease. Int J Hematol 1999; 70: 7-12.
13. de Jesus AR, Silva A, Santana LB, et al. Clinical and immunologic evaluation of 31 patients with acute schistosomiasis mansoni. J Infect Dis 2002; 185: 98-105.
14. Zwingenberger K, Irschick E, Vergetti Siqueira JG, Correia Dacal AR & Feldmeier H. Tumour necrosis factor in hepatosplenic schistosomiasis. Scand J Immunol 1990; 31: 205-211.
15. Mwatha JK, Kimani G, Kamau T, et al. High levels of TNF, soluble TNF receptors, soluble ICAM-1, and IFN-γ, but low levels of IL-5, are associated with hepatosplenic disease in human schistosomiasis mansoni. J Immunol 1998; 160: 1992-1999.
16. Wamachi AN, Mayadev JS, Mungai PL, et al. Increased ratio of tumor necrosis factor-á to interleukin-10 production is associated with Schistosoma haematobium-induced urinary-tract morbidity. J Infect Dis 2004; 190: 2020-2030.
17. Booth M, Mwatha JK, Joseph S, et al. Periportal fibrosis in human Schistosoma mansoni infection is associated with low IL-10, low IFN-γ, high TNF-α, or low RANTES, depending on age and gender. J Immunol 2004; 172: 1295-1303.
18. Brunet LR, Finkelman FD, Cheever AW, Kopf MA & Pearce EJ. IL-4 protects against TNF-α-mediated cachexia and death during acute schistosomiasis. J Immunol 1997; 159: 777-785.
19. Hesse M, Modolell M, La Flamme AC, et al. Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of 1-arginine metabolism. J Immunol 2001; 167: 6533-6544.
20. Maciejewski JP, Selleri C, Sato T, et al. Nitric oxide suppression of human hematopoiesis in vitro. Contribution to inhibitory action of interferon-γ and tumor necrosis factor-α. J Clin Invest 1995; 96: 1085-1092.
21. Hoffmann KF, Cheever AW & Wynn TA. IL-10 and the dangers of immune polarization: excessive type 1 and type 2 cytokine responses induce distinct forms of lethal immunopathology in marine schistosomiasis. J Immunol 2000; 164: 6406-6416.
22. Tilg H, Ulmer H, Kaser A & Weiss G. Role of IL-10 for induction of anemia during inflammation. J Immunol 2002; 169: 2204-2209.
23. Pyrrho AS, Lenzi HL, Ramos JA, et al. Dexamethasone treatment improves morphological and hematological parameters in chronic experimental schistosomiasis. Parasitol Res 2004; 92: 478-483.
24. Robinson A & Lewert RM. The production and nature of anemia in Schistosoma japonicum infections. Am J Trop Med Hyg 1980; 29: 1301-1306.
25. + T cell-dependent anti-erythrocyte antibody levels following the onset of parasite egg production in Schistosoma mansoni infected mice. Parasite Immunol 1994; 16: 469-477.
26. Adewusi OI, Nix NA, Lu X, Colley DG & Secor WE. Schistosoma mansoni: relationship of tumor necrosis factor-α to morbidity and collagen deposition in chronic experimental infection. Exp Parasitol 1996; 84: 115-123.
27. Tracey KJ & Cerami A. Metabolic responses to cachectin/TNF. A brief review. Ann N Y Acad Sci 1990; 587: 325-331.
28. Asahi H, Moribayashi A, Sendo F & Kobayakawa T. Hemolytic factors in Schistosoma japonicum eggs. Infect Immun 1984; 46: 514-518.
29. Quinn GAP, Heymans R, Rondaj F, Shaw C & de Jong-Brink M. Schistosoma mansoni dermaseptin-like: peptide: structural and functional characterization. J Parasitol 2005; in press.
30. Mahmoud AA & Woodruff AW. Mechanisms involved in the anaemia of schistosomiasis. Trans R Soc Trop Med Hyg 1972; 66: 75-84.
31. Stephenson L. The impact of schistosomiasis on human nutrition. Parasitol 1993; 107: S107-S123.
32. Kullberg MC, Pearce EJ, Hieny SE, Sher A & Berzofsky JA. Infection with Schistosoma mansoni alters Th1/Th2 cytokine responses to a non-parasite antigen. J Immunol 1992; 148: 3264-3270.
33. Sabin EA, Araujo MI, Carvalho EM & Pearce EJ. Impairment of tetanus toxoid-specific Th1-like immune responses in humans infected with Schistosoma mansoni. J Infect Dis 1996; 173: 269-272.
34. Frank C, Mohamed MK, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355: 887-891.
35. Rao MR, Naficy AB, Darwish MA, et al. Further evidence for association of hepatitis C infection with parenteral schistosomiasis treatment in Egypt. BMC Infect Dis 2002; 2: 29.
36. Bassily S, Dunn MA, Farid Z, et al. Chronic hepatitis B in patients with schistosomiasis mansoni. J Trop Med Hyg 1983; 86: 67-71.
37. Lyra LG, Reboucas G & Andrade ZA. Hepatitis B surface antigen carrier state in hepatosplenic schistosomiasis. Gastroenterology 1976; 71: 641-645.
38. Kamal SM, Bianchi L, Al Tawil A, et al. Specific cellular immune response and cytokine patterns in patients coinfected with hepatitis C virus and Schistosoma mansoni. J Infect Dis 2001; 184: 972-982.
39. + T cell responses in HCV and Schistosoma mansoni coinfection: relation to progression of liver fibrosis. J Infect Dis 2004; 189: 1140-1150.
40. El-Kady IM, Lotfy M, Badra G, El-Masry S & Waked I. Interleukin (IL)-4, IL-10, IL-18 and IFN-γ cytokines pattern in patients with combined hepatitis C virus and Schistosoma mansoni infections. Scand J Immunol 2005; 61: 87-91.
41. UNAIDS/WHO. AIDS epidemic update 2004. 2004.
42. Maggi E, Mazzetti M, Ravina A, et al. Ability of HIV to promote a TH1 to TH0 shift and to replicate preferentially in TH2 and TH0 cells. Science 1994; 265: 244-248.
43. Bentwich Z, Kalinkovich A & Weisman Z. Immune activation is a dominant factor in the pathogenesis of African AIDS. Immunol Today 1995; 16: 187-191.
44. Fincham JE, Markus MB & Adams VJ. Could control of soil-transmitted helminthic infection influence the HIV/AIDS pandemic. Acta Trop 2003; 86: 315-333.
45. Mwinzi PN, Karanja DM, Colley DG, Orago AS & Secor WE. Cellular immune responses of schistosomiasis patients are altered by human immunodeficiency virus type 1 coinfection. J Infect Dis 2001; 184: 488-496.
46. Secor WE, Shah A, Mwinzi PM, Ndenga BA, Watta CO & Karanja DM. Increased density of human immunodeficiency virus type 1 coreceptors CCR5 and CXCR4 on the surfaces of CD4(+) T cells and monocytes of patients with Schistosoma mansoni infection. Infect Immun 2003; 71: 6668-6671.
47. Chenine AL, Kathleen KA, Li PL, et al. Schistosoma mansoni infection promotes SHIV clade C replication in rhesus macaques. AIDS 2005; in press.
48. Lawn SD, Karanja DM, Mwinzi P, et al. The effect of treatment of schistosomiasis on blood plasma HIV-1 RNA concentration in coinfected individuals. AIDS 2000; 14: 2437-2443.
49. Brown M, Kizza M, Watera C, et al. Helminth infection is not associated with faster progression of HIV disease in coinfected adults in Uganda. J Infect Dis 2004; 190: 1869-1879.
50. Brown M, Mawa PA, Joseph S, et al. Treatment of Schistosoma mansoni infection increases helminth-specific type 2 cytokine responses and HIV-1 loads in coinfected Ugandan adults. J Infect Dis 2005; 191: 1648-1657.
51. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342: 921-929.
52. Leutscher PDC, Pedersen M, Raharisolo C, et al. Increased prevalence of leukocytes and elevated cytokine levels in semen from Schistosoma haematobium-infected individuals. J Infect Dis 2005; 191: 1639-1647.
53. Poggensee G & Feldmeier H. Female genital schistosomiasis: facts and hypotheses. Acta Trop 2001; 79: 193-210.
54. Midzi N, Ndhlovu PD, Nyanga L, et al. Assessment of eosinophil cationic protein as a possible diagnostic marker for female genital schistosomiasis in women living in a Schistosoma haematobium endemic area. Parasite Immunol 2003; 25: 581-588.
55. Mwinzi PN, Karanja DM, Kareko I, et al. Evaluation of hepatic fibrosis in persons co-infected with Schistosoma mansoni and human immunodeficiency virus 1. Am J Trop Med Hyg 2004; 71: 783-786.
56. Booth M, Vennervald BJ, Kenty L, et al. Micro-geographical variation in exposure to Schistosoma mansoni and malaria, and exacerbation of splenomegaly in Kenyan school-aged children. BMC Infect Dis 2004; 4: 13.
57. Diallo TO, Remoue F, Schacht AM, et al. Schistosomiasis coinfection in humans influences inflammatory markers in uncomplicated Plasmodium falciparum malaria. Parasite Immunol 2004; 26: 365-369.
58. Mwatha JK, Jones FM, Mohamed G, et al. Associations between anti-Schistosoma mansoni and anti-Plasmodium falciparum antibody responses and hepatosplenomegaly, in Kenyan schoolchildren. J Infect Dis 2003; 187: 1337-1341.
59. Bentwich Z, Kalinkovich A, Weisman Z, Borkow G, Beyers N & Beyers AD. Can eradication of helminthic infections change the face of AIDS and tuberculosis? Immunol Today 1999; 20: 485-487.
60. Elias D, Akuffo H, Thors C, Pawlowski A & Britton S. Low dose chronic Schistosoma mansoni infection increases susceptibility to Mycobacterium bovis BCG infection in mice. Clin Exp Immunol 2005; 139: 398-404.
61. Malhotra I, Mungai P, Wamachi A, et al. Helminth- and Bacillus Calmette-Guerin-induced immunity in children sensitized in utero to filariasis and schistosomiasis. J Immunol 1999; 162: 6843-6848.
62. Elliott AM, Kyosiimire J, Quigley MA, et al. Eosinophilia and progression to active tuberculosis in HIV-1-infected Ugandans. Trans R Soc Trop Med Hyg 2003; 97: 477-480.
63. King CH, Muchiri EM & Ouma JH. Evidence against rapid emergence of praziquantel resistance in Schistosoma haematobium, Kenya. Emerg Infect Dis 2000; 6: 585-594.
64. Fenwick A, Savioli L, Engels D, Robert Bergquist N & Todd MH. Drugs for the control of parasitic diseases: current status and development in schistosomiasis. Trends Parasitol 2003; 19: 509-515.
65. Richter J. The impact of chemotherapy on morbidity due to schistosomiasis. Acta Trop 2003; 86: 161-183.
66. Woolhouse ME & Hagan P. Seeking the ghost of worms past. Nat Med 1999; 5: 1225-1227.
67. Karanja DM, Hightower AW, Colley DG, et al. Resistance to reinfection with Schistosoma mansoni in occupationally exposed adults and effect of HIV-1 co-infection on susceptibility to schistosomiasis: a longitudinal study. Lancet 2002; 360: 592-596.
68. Colley DG & Secor WE. Immunoregulation and World Health Assembly resolution 54-19: why does treatment control morbidity? Parasitol Int 2004; 53: 143-150.
69. Roberts M, Butterworth AE, Kimani G, et al. Immunity after treatment of human schistosomiasis: association between cellular responses and resistance to reinfection. Infect Immun 1993; 61: 4984-4993.
70. + cells after chemotherapy in human Schistosoma haematobium infection. Eur J Immunol 1996; 26: 1365-1370.
71. Grogan JL, Kremsner PG, Decider AM & Yazdanbakhsh M. Antigen-specific proliferation and interferon-γ and interleukin-5 production are down-regulated during Schistosoma haematobium infection. J Infect Dis 1998; 177: 1433-1437.
72. Medhat A, Shehata M, Bucci K, et al. Increased interleukin-4 and interleukin-5 production in response to Schistosoma haematobium adult worm antigens correlates with lack of reinfection after treatment. J Infect Dis 1998; 178: 512-519.
73. Joseph S, Jones FM, Laidlaw ME, et al. Impairment of the Schistosoma mansoni-specific immune responses elicited by treatment with praziquantel in Ugandans with HIV-1 coinfection. J Infect Dis 2004; 190: 613-618.
74. Joseph S, Jones FM, Walter K, et al. Increases in human T helper 2 cytokine responses to Schistosoma mansoni worm and worm-tegument antigens are induced by treatment with praziquantel. J Infect Dis 2004; 190: 835-842.
75. Mduluza T, Ndhlovu PD, Midzi N, et al. Contrasting cellular responses in Schistosoma haematobium infected and exposed individuals from areas of high and low transmission in Zimbabwe. Immunol Lett 2003; 88: 249-256.
76. Butterworth AE, David JR, Franks D, et al. Antibody-dependent eosinophil-mediated damage to 51Cr-labeled schistosomula of Schistosoma mansoni: damage by purified eosinophils. J Exp Med 1977; 145: 136-150.
77. Hagan P, Wilkins HA, Blumenthal UJ, Hayes RJ & Greenwood BM. Eosinophilia and resistance to Schistosoma haematobium in man. Parasite Immunol 1985; 7: 625-632.
78. Hagan P, Blumenthal UJ, Dunn D, Simpson AJ & Wilkins HA. Human IgE, IgG4 and resistance to reinfection with Schistosoma haematobium. Nature 1991; 349: 243-245.
79. Rihet P, Demeure CE, Bourgois A, Prata A & Dessein AJ. Evidence for an association between human resistance to Schistosoma mansoni and high anti-larval IgE levels. Eur J Immunol 1991; 21: 2679-2686.
80. Dunne DW, Butterworth AE, Fulford AJ, et al. Immunity after treatment of human schistosomiasis: association between IgE antibodies to adult worm antigens and resistance to reinfection. Eur J Immunol 1992; 22: 1483-1494.
81. Zhang Z, Wu H, Chen S, et al. Association between IgE antibody against soluble egg antigen and resistance to reinfection with Schistosoma japonicum. Trans R Soc Trop Med Hyg 1997; 91: 606-608.
82. Grogan JL, Kremsner PG, van Dam GJ, Decider AM & Yazdanbakhsh M. Anti-schistosome IgG4 and IgE at 2 years after chemotherapy: infected versus uninfected individuals. J Infect Dis 1997; 176: 1344-1350.
83. Grogan JL, Kremsner PG, van Dam GJ, et al. Antischistosome IgG4 and IgE responses are affected differentially by chemotherapy in children versus adults. J Infect Dis 1996; 173: 1242-1247.
84. Kabatereine NB, Vennervald BJ, Ouma JH, et al. Adult resistance to schistosomiasis mansoni: age-dependence of reinfection remains constant in communities with diverse exposure patterns. Parasitology 1999; 118: 101-105.
85. Butterworth AE, Fulford AJ, Dunne DW, Ouma JH & Sturrock RF. Longitudinal studies on human schistosomiasis. Phil Trans R Soc Lond B Biol Sci 1988; 321: 495-511.
86. Fallon PG, Gibbons J, Vervenne RA, et al. Juvenile rhesus monkeys have lower type 2 cytokine responses than adults after primary infection with Schistosoma mansoni. J Infect Dis 2003; 187: 939-945.
87. Marquet S, Abel L, Hillaire D, et al. Genetic localization of a locus controlling the intensity of infection by Schistosoma mansoni on chromosome 5q31-q33. Nat Genet 1996; 14: 181-184.
88. Muller-Myhsok B, Stelma FF, Guisse-Sow F, et al. Further evidence suggesting the presence of a locus, on human chromosome 5q31-q33, influencing the intensity of infection with Schistosoma mansoni. Am J Hum Genet 1997; 61: 452-454.
89. Kouriba B, Chevillard C, Bream JH, et al. Analysis of the 5q31-q33 locus shows an association between IL13-1055C/T IL13-591A/G polymorphisms and Schistosoma haematobium infections. J Immunol 2005; 174: 6274-6281.
90. Scott JT, Vereecken K, Diakhate MM, et al. Are the cellular immune responses of children and adults with Schistosoma mansoni infection intrinsically different? Cytokines produced ex vivo in response to antigens and mitogens. Parasite Immunol 2004; 26: 29-36.
91. Abebe F, Gaarder PI, Petros B & Gundersen SG. Differences in prevalence, intensity of infection and parasite-specific antibody levels do not predict different age-infection profiles. APMIS 2002; 110: 535-544.
92. King CH, Blanton RE, Muchiri EM, et al. Low heritable component of risk for infection intensity and infection-associated disease in urinary schistosomiasis among Wadigo village populations in Coast Province, Kenya. Am J Trop Med Hyg 2004; 70: 57-62.
93. Bethony J, Silveira AM, Alves-Oliveira LF, et al. Familial resemblance in humoral immune response to defined and crude Schistosoma mansoni antigens in an endemic area in Brazil. J Infect Dis 1999; 180: 1665-1673.